


# Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

## Supplemental Figure 3. CD8 positive cells in tumors at baseline and post-treatment

Average number of CD8 positive cells were detected by IHC in approximately 5 randomly selected high power microscopic fields from baseline (black) and post-baseline (grey) tumor biopsies for each patient in Cohorts A1-A4.



Abbreviation: HPF, high-power microscopic fields.  
Note: Data for 1 patient in Cohort A1 was not available.